Protocol 1: Conservative foundation (beginners) Goal: Gentle immune modulation with minimal risk Components: Thymosin alpha-1: 1.6 mg subcutaneously, twice weekly BPC-157: 250 mcg subcutaneously, once daily (abdominal injection for gut support) Schedule: Monday and Thursday: Thymosin alpha-1 Daily: BPC-157 in the morning Duration: 8 weeks on, 4 weeks off Monitoring: Baseline labs before starting, repeat at week 4 and week 8
To assess cell viability of the neurospheres, cells were seeded after dissociation in 100 L PrimNeuS media on a Nunclon Sphera 96-Well U-Shaped-Bottom Microplate (Thermo Scientific)
With a favorable safety profile based on the research to date, BPC-157 is actively studied in contexts of wound healing, injury recovery, neuroprotection, and muscle repair
Modulation of Growth Hormone Fragment Pathways : AOD-9604 represents the modified fragment 177-191 of human growth hormone , designed to retain the fat-burning properties of HGH without its systemic growth or insulin-like effects